Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) is a Healthcare company (Biotechnology) with a market capitalization of $80M. The Maz Rating grades it against the other companies in its sector.
Polaryx Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $1.60, Polaryx Therapeutics, Inc. Common Stock trades at 10.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -136.7%, return on invested capital of -99.6% and a free cash flow yield of -10.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 8.62. Over the past 52 weeks the share price ranged from $1.58 to $48.91, with a beta of -8.28.
Polaryx Therapeutics, Inc. Common Stock does not currently pay a dividend.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.